Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
about
Clinical development of Ebola vaccinesDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsCircumventing antivector immunity: potential use of nonhuman adenoviral vectorsBoth haemagglutinin-specific antibody and T cell responses induced by a chimpanzee adenoviral vaccine confer protection against influenza H7N9 viral challenge.Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in ChinaThe influence of delivery vectors on HIV vaccine efficacyThe sero-prevalence of anti-adenovirus 5 neutralizing antibodies is independent of a chronic hepatitis B carrier state in ChinaProtective efficacy of recombinant canine adenovirus type-2 expressing TgROP18 (CAV-2-ROP18) against acute and chronic Toxoplasma gondii infection in mice.Adenovirus Specific Pre-Immunity Induced by Natural Route of Infection Does Not Impair Transduction by Adenoviral Vaccine Vectors in Mice.Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China.Ebola virus vaccine: benefit and risks of adenovirus-based vectors.The prevalence of neutralising antibodies to chimpanzee adenovirus type 6 and type 7 in healthy adult volunteers, patients with chronic hepatitis B and patients with primary hepatocellular carcinoma in China.Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China.Chimpanzee adenoviral vectors as vaccines - challenges to move the technology into the fast lane.Simian adenoviruses as vaccine vectors.Seroprevalence of Neutralizing Antibodies against Human Adenovirus Type-5 and Chimpanzee Adenovirus Type-68 in Cancer Patients.
P2860
Q26775792-BBB65EE1-127A-45C4-88A7-4C17AAE5726BQ26782083-7CE4F832-25DF-4E3A-ABB8-CECA3A4AFB6EQ26995655-127D06A6-FAE2-4F94-A075-E55D2E1A18CEQ33687181-3EAAAA2F-24CB-49B9-8936-23EDEBDF4BE3Q33733003-F1C6B2F8-42C6-41E8-808F-EB2E7BCBBD59Q34077543-22EBFE0A-EBD4-4B25-B9EB-8A7FED7BAC17Q35204923-918F8E16-E8B7-476B-B19C-9743F48D75DAQ35425382-671BD574-094C-4746-A3AC-4D968CC20FA7Q35871976-A904A6D2-FAA1-4F53-B624-05ADA182932BQ36829831-BE6C635E-8870-487B-A534-053294C416A5Q38577875-A539D3E8-F17D-44EF-998B-0970610E0324Q39346309-2D514A96-BB9C-42D7-B4FC-4CC715228EA8Q40170219-259A5470-C1F5-4B7C-B7AA-712FC7D0B228Q47607706-76F101A7-91A0-420F-A890-B3C4561860ACQ54531277-618334F6-AF87-4A59-80AD-E0C7D0137756Q55079945-B52D7DE5-FCAE-4255-AD8E-DC9C29FCE346
P2860
Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Seroprevalence of neutralizing ...... -68 in healthy Chinese adults.
@en
Seroprevalence of neutralizing ...... -68 in healthy Chinese adults.
@nl
type
label
Seroprevalence of neutralizing ...... -68 in healthy Chinese adults.
@en
Seroprevalence of neutralizing ...... -68 in healthy Chinese adults.
@nl
prefLabel
Seroprevalence of neutralizing ...... -68 in healthy Chinese adults.
@en
Seroprevalence of neutralizing ...... -68 in healthy Chinese adults.
@nl
P2093
P2860
P921
P356
P1476
Seroprevalence of neutralizing ...... -68 in healthy Chinese adults.
@en
P2093
Qiquan Zhao
Shujun Zhang
Wenxiang Huang
Xiangyang Zhou
P2860
P304
P356
10.1002/JMV.23546
P577
2013-06-01T00:00:00Z